Shared ligand-blocking mechanism but distinct conformational modulation by α5-targeting antibodies BIIG2 and...

Area of Science:

• Biochemistry
• Cell Biology
• Immunology

Background:

• Integrins, like α5β1 (fibronectin receptor), are crucial for cell adhesion and signaling, mediating angiogenesis.
• Dysregulation of α5β1 integrin is linked to tumor growth and metastasis.
• Current α5β1-targeting therapies face challenges with efficacy and off-target effects due to incompletely understood integrin conformation dynamics.

Purpose of the Study:

• To characterize two anti-α5β1 antibodies, BIIG2 and MINT1526A, for their therapeutic potential and mechanistic effects on integrin conformation.
• To elucidate the molecular interactions between antibodies and α5β1 integrin.
• To provide insights for designing improved integrin-targeted therapeutics.

Main Methods:

• Cell biology assays to assess angiogenesis inhibition.
• Biophysical methods to determine antibody binding affinity.
• Electron microscopy to map antibody-integrin interfaces.
• In vivo studies using xenograft mouse models to evaluate tumor growth reduction.

Main Results:

• Both BIIG2 and MINT1526A antibodies bind α5β1 integrin with nanomolar affinity and inhibit angiogenesis in vitro.
• BIIG2 demonstrated significant tumor growth reduction in xenograft models and specificity for fibroblasts and melanoma cells.
• Electron microscopy revealed overlapping epitopes and steric hindrance of fibronectin binding, but distinct effects on α5β1 conformational flexibility: MINT1526A constricted flexibility, while BIIG2 did not.

Conclusions:

• BIIG2 and MINT1526A antibodies inhibit α5β1-mediated angiogenesis and fibronectin binding through steric hindrance.
• The distinct impacts on integrin conformational states highlight the importance of conformational dynamics in therapeutic design.
• Understanding these mechanistic differences is key to developing future α5β1-targeting drugs with enhanced efficacy and minimized off-target effects.